13F Holdings
中文EN

CLPT ClearPoint Neuro, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1285550 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY32.5%
TTM net income YoY-56.2%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—

Margins

Gross margin61.4%
Operating margin-70.6%
Net margin-79.4%
FCF margin-106.0%
EBITDA margin-69.3%

Returns

ROE-167.5%
ROA-41.8%
ROIC (approx.)-130.8%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets75.8%
Debt / equity1.86x
Current ratio6.76x
Interest coverage-6.03x

Cash quality & payout

Operating cash flow / net income1.31x
Accruals ratio12.7%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$36.97M$31.39M$23.95M$20.55M$16.30M
Cost of revenue$14.28M$12.27M$10.34M$7.02M$5.18M
Gross profit$22.69M$19.12M$13.61M$13.53M$11.12M
R&D expense$13.90M$12.39M$11.71M$10.89M$9.28M
SG&A expense$16.50M$11.99M$11.76M$9.61M$8.00M
Operating income-$24.16M-$19.73M-$22.45M-$16.33M-$13.37M
Interest expense$2.39M$518,000—$81,000$973,000
Pretax income-$25.48M-$18.90M———
Income tax$55,000$12,000$8,000$0$0
Net income-$25.54M-$18.91M-$22.09M-$16.43M-$14.41M
EBITDA-$23.35M-$18.75M-$21.82M-$16.09M-$13.21M
EPS (basic)-0.90-0.70-0.90-0.68-0.69
EPS (diluted)-0.90-0.70-0.90-0.68-0.69
Weighted avg. shares (diluted)28.32M27.03M24.61M24.18M20.73M
Banking
Net interest income—$872,000$386,000-$81,000—
Balance sheet
Cash & equivalents$45.92M$20.10M$23.14M$27.61M$54.11M
Short-term investments——$0$9.87M$0
Receivables$6.55M$4.71M$3.21M$2.67M$2.34M
Inventory$8.36M$6.86M$7.91M$9.30M$4.94M
Current assets$63.60M$33.36M$36.17M$51.18M$61.89M
PP&E, net$2.62M$2.00M$1.39M$806,000$539,000
Goodwill$7.47M$7.47M———
Intangibles$13.92M$0———
Total assets$97.75M$39.19M$42.66M$55.49M$65.58M
Current liabilities$10.77M$10.35M$7.43M$6.79M$4.75M
Long-term debt$49.08M—$9.95M$9.89M$9.84M
Total debt$49.08M—$9.95M$9.89M$9.84M
Total liabilities$69.73M$13.80M$21.49M$18.60M$16.79M
Shareholders' equity$28.02M$25.39M$21.17M$36.89M$48.79M
Net debt$3.15M—-$13.19M-$17.72M-$44.27M
Shares outstanding29.37M27.62M24.65M24.58M23.67M
Cash flow statement
Operating cash flow-$23.93M-$8.95M-$13.72M-$16.17M-$12.70M
Capital expenditure$522,000$275,000$717,000$253,000$168,000
Free cash flow-$24.45M-$9.22M-$14.44M-$16.42M-$12.87M
Investing cash flow$615,000-$275,000$8.95M-$10.74M-$168,000
Financing cash flow$50.18M$6.19M$296,000$409,000$46.88M
Depreciation & amortization$814,000$980,000$626,000$244,000$159,000
Stock-based compensation$8.18M$6.91M$6.08M$4.13M$2.08M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.